Immunwork, Inc. located in Taipei, Taiwan was founded in October 2014.
After a corporate reorganization in November 2019, Immunwork is now a wholly owned subsidiary of T-E Pharma Holding, incorporated in Cayman Island. Immunwork focuses on the research and development of a class of new drugs, which are created based on our proprietary “T-ETM pharmaceuticals” technology platform. The first group of new drugs is for treating several types of cancer, diabetes, obesity, fatty liver diseases, and pathological blood clots.
A T-E pharmaceutical contains both a targeting (T) and an effector (E) moiety. The targeting moiety directs the drug molecule to specific tissues, proteins, or cells, and the effector moiety performs the intended therapeutic functions. These designs help to improve drug’s overall efficacy and safety.
The T-E technology platform is built upon the multi-arm linkers core platform, enabling the precise conjugation of targeting or effector moieties. This platform has evolved into three major sub-platforms: Fatty Acid Bundle, Antibody-Drug Conjugates (ADC), and Antibody-Radionuclide Conjugates (ARC).
The Fatty Acid Bundle technology and its derivative therapeutics are continuously developed by Immunwork, while ADC and ARC technologies, along with their associated products, are the focus of T-E Meds (https://www.temeds.com/), Immunwork’s sister company. These platforms facilitate the rapid creation of novel drug molecules, with broad applications in clinical development.
Two ultra-long-acting drug candidates developed using the Fatty Acid Bundle platform —TE-8105 and TE-8214—have entered human clinical trials, demonstrating excellent tolerability and no significant adverse effects. These advancements highlight the potential of our platform to revolutionize drug development, offering superior treatments with improved patient outcomes.